|Incidence: || |
3,170 (Estimated new cases for 2014 in the United States)
Incidence of clear cell adenocarcinoma as a result of in utero diethylstilbestrol
(DES) exposure estimated at 1/1000
|Stage at presentation |
|Stage I: ||28% |
|Stage II: ||43% |
|Deaths: ||Estimated 880 in 2014 ||Stage III: ||16% |
|Median age: ||Squamous cell cancer (60–65 years); DES-related adenocarcinoma/clear cell (19 years) ||Stage IV: ||13% |
Daling JR et al. Gynecol Oncol 2002;84:263–270
Siegel R et al. CA Cancer J Clin 2014;64:9–29
Tedeschi C et al. J Low Genit Tract Dis 2005;9:11–18
Histologic Classification of Vaginal Neoplasia
VAIN (VAginal Intraepithelial Neoplasms)
These are pre-malignant lesions of the vaginal squamous epithelium that can develop primarily in the vagina or as an extension from the cervix. Histologically, VAIN is defined in the same way as cervical intraepithelial neoplasia (CIN). Classification includes three grades: Grade 1 (VAIN I = mild dysplasia); Grade 2 (VAIN II = moderate dysplasia); and Grade 3 (VAIN III = severe dysplasia or carcinoma in situ)
|1. Squamous cell carcinoma ||88% |
|2. Adenocarcinoma ||5% |
|3. Other epithelial cell types (adenosquamous, adenoid cystic, undifferentiated) ||1–2% |
|4. Mesenchymal tumors (leiomyosarcoma, sarcoma botryoides, endometrioid sarcoma) ||2% |
|5. Mixed epithelial and mesenchymal tumors ||<1% |
|6. Other histologies (melanoma, sarcoma, yolk sac tumors, lymphoma, carcinoid, small cell) ||3–4% |
Higinia R et al. Vagina. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott-Raven, 2005:707–742
Zaino RJ, Robboy SJ, Kurman RJ. Diseases of the vagina. In: Blaustein's Pathology of the Female Genital Tract. 5th ed. New York: Springer-Verlag, 2002:178–195
VAIN (vaginal intraepithelial neoplasia):
H&P, including bimanual examination, palpation, and colposcopic examination of the vagina, vulva, and cervix
Multiple site-directed biopsies, including cervical and vulvar biopsies, to rule out invasive disease and metastatic lesions
H&P including bimanual examination and palpation of vagina
Multiple site-directed biopsies, including cervical biopsies to rule out invasive disease and primary cervical cancer
Studies allowable for staging as per FIGO✫ guidelines: chest X-ray, cystoscopy, proctosigmoidoscopy, and intravenous pyelogram. Although not part of staging, pelvic MRI or CT scan may aid in planning of patient care
If clinically warranted, barium enema and CAT scan or MRI
Staging is best performed by gynecologic and radiation oncologists with the patient under general anesthesia. Additional biopsies of the vagina should be done to determine the limits of abnormal vaginal mucosa
|TNM Category ||FIGO Stage ||Primary Tumor (T) |
|TX || ||Primary tumor cannot be assessed |
|T0 || ||No evidence of primary tumor |
|Tis ||✫ || |
Carcinoma in situ
|T1 ||I ||Tumor confined to vagina |
|T2 ||II ||Tumor invades paravaginal tissues but not to pelvic wall |
|T3 ||III |
Tumor extends to pelvic ...
Log In to View More
If your institution is currently a subscriber
of the HemOnc Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.